Nuvation Bio Inc. Class A Common Stock vs Health Care Select Sector SPDR Fund — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while Health Care Select Sector SPDR Fund trades at $168.14 (market cap $43.11B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 25.2× Nuvation Bio Inc. Class A Common Stock's market cap, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| NUVB | XLV | |
|---|---|---|
Market Cap | $1.71B | $43.11B |
Volume | 5,448,712 | 8,870,090 |
Sector | Health | — |
52-Week High | $9.54 | $175.68 |
52-Week Low | $3.41 | $141.95 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $1.30B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLV trades at $168.81, up 1.03% with a bullish technical signal from moving averages. The healthcare ETF shows strength with 61 diversified holdings and a low 0.08% expense ratio. Recent news highlights its defensive characteristics during market volatility and potential benefits from rising interest rates. Technical indicators show support at $168 with resistance at $170, while oscillators remain neutral.
XLV offers defensive exposure to healthcare with cost efficiency, though concentration in S&P 500 stocks limits global diversification. Political uncertainty and sector-specific risks like FDA approvals present challenges, but the ETF's broad diversification and historical performance during rate hikes support a constructive outlook for long-term investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →